HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert A Harrington Selected Research

Purinergic P2Y Receptor Antagonists

12/2018Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial.
1/2017Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
12/2011Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
12/2009Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
11/2007Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial.
11/2007Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert A Harrington Research Topics

Disease

169Acute Coronary Syndrome
08/2022 - 07/2001
165Myocardial Infarction
12/2022 - 07/2001
121Hemorrhage
03/2022 - 01/2002
57Thrombosis (Thrombus)
03/2022 - 05/2002
52Stroke (Strokes)
12/2022 - 12/2002
44Ischemia
03/2022 - 02/2002
28Unstable Angina
08/2022 - 07/2001
26ST Elevation Myocardial Infarction
06/2022 - 04/2003
21Coronary Artery Disease (Coronary Atherosclerosis)
12/2022 - 01/2002
21Cardiovascular Diseases (Cardiovascular Disease)
01/2021 - 06/2002
19Heart Failure
01/2018 - 01/2003
18Coronary Disease (Coronary Heart Disease)
08/2022 - 05/2002
15Infarction (Infarctions)
11/2013 - 06/2002
14Venous Thromboembolism
01/2019 - 09/2004
9Diabetes Mellitus
12/2022 - 06/2005
9Ischemic Stroke
08/2022 - 09/2004
8Atrial Fibrillation
01/2022 - 09/2004
7Venous Thrombosis (Deep-Vein Thrombosis)
12/2018 - 03/2017
7Chronic Renal Insufficiency
04/2014 - 03/2008
6Intracranial Hemorrhages (Intracranial Hemorrhage)
01/2022 - 04/2003
5Pathologic Constriction (Stenosis)
09/2019 - 11/2008
5Renal Insufficiency (Renal Failure)
01/2019 - 09/2006
5Stable Angina
11/2018 - 05/2012
5Myocardial Ischemia (Ischemic Heart Diseases)
01/2018 - 10/2004
5Pulmonary Embolism
01/2018 - 03/2017
4Type 2 Diabetes Mellitus (MODY)
12/2022 - 05/2019
4Inflammation (Inflammations)
06/2022 - 04/2007
4Necrosis
06/2022 - 03/2008
4Non-ST Elevated Myocardial Infarction
02/2022 - 04/2007
4Dyslipidemias (Dyslipidemia)
01/2022 - 08/2014
4Cerebrovascular Disorders (Cerebrovascular Occlusion)
11/2013 - 07/2003
4Reperfusion Injury
11/2013 - 11/2005
4Cardiogenic Shock
12/2012 - 04/2007
4Vascular Diseases (Vascular Disease)
11/2008 - 07/2003
4Hypersensitivity (Allergy)
06/2008 - 09/2004

Drug/Important Bio-Agent (IBA)

65Clopidogrel (Plavix)FDA Link
01/2022 - 09/2004
35TicagrelorIBA
12/2022 - 11/2007
34Eptifibatide (Integrilin)FDA Link
04/2017 - 07/2001
33Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
12/2022 - 06/2002
33Glycoproteins (Glycoprotein)IBA
01/2018 - 01/2002
32cangrelorIBA
03/2022 - 03/2006
20vorapaxarIBA
12/2018 - 03/2009
19Thrombin Receptors (Thrombin Receptor)IBA
01/2020 - 01/2012
18Enoxaparin (Lovenox)FDA LinkGeneric
01/2019 - 10/2003
17Platelet Membrane GlycoproteinsIBA
02/2008 - 07/2001
15Biomarkers (Surrogate Marker)IBA
06/2022 - 02/2004
15Heparin (Liquaemin)FDA LinkGeneric
03/2019 - 08/2002
15Platelet Membrane Glycoprotein IIbIBA
01/2018 - 12/2002
15Pharmaceutical PreparationsIBA
01/2018 - 01/2002
14Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
08/2022 - 07/2004
14alirocumabIBA
08/2022 - 11/2014
14AnticoagulantsIBA
01/2019 - 05/2002
12betrixabanIBA
01/2019 - 11/2016
11paragonIBA
12/2010 - 02/2002
10omega-Chloroacetophenone (Mace)IBA
08/2022 - 11/2012
10CreatinineIBA
08/2016 - 07/2003
9apixabanIBA
01/2020 - 06/2009
9StreptokinaseFDA Link
06/2019 - 07/2002
9bivalirudin (Angiomax)FDA Link
01/2017 - 02/2003
9MB Form Creatine KinaseIBA
11/2009 - 09/2003
8LDL CholesterolIBA
08/2022 - 11/2008
8AntithrombinsIBA
09/2010 - 02/2003
8TenecteplaseFDA Link
03/2005 - 04/2003
7oxidized low density lipoproteinIBA
12/2020 - 11/2008
7fibrin fragment D (D-dimer)IBA
01/2019 - 03/2017
7Tissue Plasminogen Activator (Alteplase)FDA Link
01/2018 - 09/2004
7EnzymesIBA
05/2014 - 02/2002
6Proprotein Convertase 9IBA
08/2022 - 11/2018
6pro-brain natriuretic peptide (1-76)IBA
06/2022 - 01/2014
6TroponinIBA
02/2022 - 01/2006
6Purinergic P2Y Receptor AntagonistsIBA
12/2018 - 11/2007
6Factor Xa InhibitorsIBA
01/2017 - 05/2002
5C-Reactive ProteinIBA
06/2022 - 04/2010
5CholesterolIBA
12/2020 - 11/2007
5Glucose (Dextrose)FDA LinkGeneric
01/2019 - 03/2010
5Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA
12/2015 - 07/2003
5Abciximab (ReoPro)FDA Link
03/2006 - 09/2002
4Growth Differentiation Factor 15IBA
06/2022 - 01/2014
4Peptide Hydrolases (Proteases)FDA Link
12/2018 - 03/2014
4CalciumIBA
12/2016 - 01/2007
4Fibrinolytic Agents (Antithrombotic Agents)IBA
06/2015 - 09/2004
4MetalsIBA
09/2014 - 01/2007
4Creatine Kinase (Creatine Phosphokinase)IBA
11/2009 - 01/2006
3Lipoproteins (Lipoprotein)IBA
08/2022 - 01/2019
3ApolipoproteinsIBA
08/2022 - 11/2018
3N(2)-(3-trifluoromethylphenyl)guanineIBA
06/2022 - 05/2004
3Brain Natriuretic Peptide (Natrecor)FDA Link
06/2022 - 10/2017
3Interleukin-6 (Interleukin 6)IBA
06/2022 - 04/2010
3Troponin T (Troponin T1)IBA
06/2022 - 02/2003
3HDL LipoproteinsIBA
12/2020 - 08/2014

Therapy/Procedure

119Therapeutics
08/2022 - 07/2001
78Percutaneous Coronary Intervention
12/2022 - 06/2002
45Stents
03/2022 - 02/2003
38Coronary Artery Bypass (Coronary Artery Bypass Surgery)
09/2019 - 01/2002
11Patient Readmission
01/2018 - 07/2008
11Blood Transfusion (Blood Transfusions)
01/2018 - 07/2004
10Thrombolytic Therapy
02/2022 - 01/2003
7Drug-Eluting Stents
03/2019 - 06/2003
6Secondary Prevention
01/2020 - 08/2003
4Cardiopulmonary Bypass (Heart-Lung Bypass)
01/2017 - 04/2008